Can a common asthma drug stop post-transplant fevers?
NCT ID NCT05509933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug budesonide can prevent fevers caused by engraftment syndrome after a stem cell transplant. About 110 adults with blood cancers will receive budesonide starting 5 days after transplant, and researchers will compare their fever rates to those who do not get the drug. The goal is to reduce non-infectious fevers and improve recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENGRAFTMENT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient herb, modern hope: ashwagandha compound tested to prevent deadly transplant complication
- Ancient herb takes on transplant complication: Withaferin-A tested for Steroid-Resistant GVHD
- New program helps caregivers of stem cell patients cope better
- New antibiotic could shield blood cancer patients from deadly infections
- New study aims to decode Post-Transplant complication risks
- Immune booster after transplant shows promise for blood cancer patients